Novavax (NASDAQ: NVAX) is a biotech at the center stage of the investment world right now as it works to create a vaccine against SARS-CoV-2. This is undoubtedly a colossal venture; a successful vaccine could save countless lives and allow economies around the world to safely reopen.
With so much interest, investors may feel uncomfortable purchasing shares of Novavax right now, fearing the company's growth outlook is already part of its share price. However, there are at least three reasons why Novavax's momentum is likely to continue.
Image source: Getty Images.
Source Fool.com